CNSP Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -- compared to CNS Pharmaceuticals's net margin of --. CNS Pharmaceuticals's return on equity of -- beat Nanoviricides's return on equity of --.

CNS Pharmaceuticals has a consensus price target of $200.00, signalling upside risk potential of 17599.12%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 490.91%. Given that CNS Pharmaceuticals has higher upside potential than Nanoviricides, analysts believe CNS Pharmaceuticals is more attractive than Nanoviricides.

CNS Pharmaceuticals has a beta of 1.085, which suggesting that the stock is 8.495% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.927, suggesting its less volatile than the S&P 500 by 7.287%.

CNS Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

CNS Pharmaceuticals quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. CNS Pharmaceuticals's net income of -$5.6M is lower than Nanoviricides's net income of -$2M. Notably, CNS Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to CNS Pharmaceuticals's net margin of --. CNS Pharmaceuticals's return on equity of -- beat Oragenics's return on equity of --.

CNS Pharmaceuticals has a consensus price target of $200.00, signalling upside risk potential of 17599.12%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 426.32%. Given that CNS Pharmaceuticals has higher upside potential than Oragenics, analysts believe CNS Pharmaceuticals is more attractive than Oragenics.

CNS Pharmaceuticals has a beta of 1.085, which suggesting that the stock is 8.495% more volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.

CNS Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

CNS Pharmaceuticals quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. CNS Pharmaceuticals's net income of -$5.6M is lower than Oragenics's net income of -$3.3M. Notably, CNS Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals is -- versus 1.18x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to CNS Pharmaceuticals's net margin of -2357.27%. CNS Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

CNS Pharmaceuticals has a consensus price target of $200.00, signalling upside risk potential of 17599.12%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1483.71%. Given that CNS Pharmaceuticals has higher upside potential than Palatin Technologies, analysts believe CNS Pharmaceuticals is more attractive than Palatin Technologies.

CNS Pharmaceuticals has a beta of 1.085, which suggesting that the stock is 8.495% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

CNS Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

CNS Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. CNS Pharmaceuticals's net income of -$5.6M is lower than Palatin Technologies's net income of -$2.4M. Notably, CNS Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to CNS Pharmaceuticals's net margin of --. CNS Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

CNS Pharmaceuticals has a consensus price target of $200.00, signalling upside risk potential of 17599.12%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 471.43%. Given that CNS Pharmaceuticals has higher upside potential than Theriva Biologics, analysts believe CNS Pharmaceuticals is more attractive than Theriva Biologics.

CNS Pharmaceuticals has a beta of 1.085, which suggesting that the stock is 8.495% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

CNS Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

CNS Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. CNS Pharmaceuticals's net income of -$5.6M is lower than Theriva Biologics's net income of -$4.4M. Notably, CNS Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.